Pharmaceutical giant Pfizer has been ordered to pay $142 million US in damages for fraudulently marketing Gabapentin, an anti-seizure drug marketed under the name Neurontin. Data revealed in a string of U.S. lawsuits indicates the drug was promoted by the drug company as a treatment for pain, migraines and bipolar disorder; however it wasn’t effective in treating these conditions and was actually toxic in certain cases. The trials forced the company to release all of its studies on the drug, including the ones it kept hidden. A new analysis of those unpublished trials by the Therapeutics Initiative suggests that Gabapentin works for one out of every six or eight people who use it. Pfizer defends its actions and its drug. The company has already been hit with $430 million in penalties and fines for fraudulently promoting Gabapentin in the U.S.